aNew York University School of Medicine bDivision of Rheumatology, Department of Medicine, New York University School of Medicine, New York, New York, USA.
Curr Opin Rheumatol. 2014 Jan;26(1):101-7. doi: 10.1097/BOR.0000000000000008.
Despite the progress toward understanding the molecular pathogenesis of rheumatoid arthritis (RA), its cause remains elusive. Genes are important but rather insufficient to explain the majority of RA cases. This review describes the novel data supporting the microbiome and its interactions with the human host as potential en('in')vironmental factors in RA pathogenesis.
Animal models of inflammatory arthritis have shown that the presence of bacteria in mucosal surfaces is sufficient to alter local and systemic host immune responses and elicit joint inflammation. Human RA studies have focused on three mucosal sites: the gut, the gingiva, and the respiratory tree. The oral microbiome, and specifically Porphyromonas gingivalis, has long been implicated. Novel sequencing technologies have allowed investigations into the role of the gut microbiome in the development of autoimmune arthritis. Most recently, the pulmonary parenchyma has also been described as yet another possible mucosal site of initiation of autoimmunity in RA.
Emerging data implicate the microbiome in RA pathogenesis. Mucosal sites exposed to a high load of bacterial antigens--such as the periodontium, lung, and gut--may represent the initial site of autoimmune generation. If validated, these findings could lead to the discovery of potential biomarkers and therapeutic approaches in the preclinical and clinical phases of RA.
尽管人们在理解类风湿关节炎(RA)的分子发病机制方面取得了进展,但该病的病因仍不明确。基因固然重要,但对于大多数 RA 病例而言,它们的作用相当有限。本综述介绍了一些新的数据,这些数据支持微生物组及其与人类宿主的相互作用可能是 RA 发病机制中的潜在环境因素。
炎症性关节炎的动物模型表明,黏膜表面存在细菌足以改变局部和全身宿主免疫反应,并引发关节炎症。RA 的人类研究集中在三个黏膜部位:肠道、牙龈和呼吸道。口腔微生物组,特别是牙龈卟啉单胞菌,长期以来一直被认为与之相关。新型测序技术已允许研究肠道微生物组在自身免疫性关节炎发展中的作用。最近,肺实质也被描述为 RA 中自身免疫起始的另一个可能的黏膜部位。
新出现的证据提示微生物组与 RA 发病机制有关。暴露于大量细菌抗原的黏膜部位,如牙周组织、肺部和肠道,可能代表自身免疫发生的初始部位。如果得到证实,这些发现可能会导致在 RA 的临床前和临床阶段发现潜在的生物标志物和治疗方法。